China has been trying to circumvent the major coronavirus outbreak without the tools it could have used several months ago, the type of vaccine it claims provides the best protection against adverse effects from COVID -19.
In the early spring of 2020, a Chinese pharmaceutical company, Fosun Pharma, reached an agreement to distribute – and produce – mRNA vaccines by Pfizer and BioNTech. It has not yet been cleared in mainland China, despite permission from various authorities to use it in Hong Kong and Macao.
Now health experts say delays – the result of politically motivated the size of the country up public health-It could lead to unavoidable coronavirus deaths and massive economic losses because cities will be completely closed to encroach on unprotected population.
“The main issue is the delay in opening the project,” said Xi Chen, an economist at Yale University School of Public Health. “The consequences will be huge, broken supply chain, and disruptions for all types of service departments.”
Studies have repeatedly shown that mRNA injections by Pfizer-BioNTech and Moderna provide the best protection against hospitalization and death from COVID-19. Chinese vaccines made with advanced technology have proven effective on the original strain of the virus, but much more than recent variations.
As this evidence becomes clearer, even countries that first introduced Chinese vaccines and some less effective Western ones have turned to mRNA vaccines to increase the effectiveness of the shot and new vaccines.
Not China. Authorities have not publicly stated why they do not work – mRNA injections have been approved in many parts of the world and have proven safe and effective in hundreds of millions of people. However, a Chinese health official and a person in direct contact with the Associated Press told the Associated Press that the authorities had withdrawn because they wanted to know more about the technology in China and not rely on suppliers. and foreign goods. They all spoke on condition of anonymity, given the seriousness of the situation.
For more than a year, the system has seemed like a protection. The country has been able to protect the virus more than any other major nation with its strict system of “zero COVID” which isolates infected people and locks communities when the outbreak occurs.
But now, the fast-moving omicron variant is testing that strategy, requiring more locks and resistance which are doing great harm to the economy and humanity. While other countries may be working closer to the norm because their people are getting vaccinated or infected in the past, China has abandoned its locking strategy only to avoid the number of hospitals and deaths.
China may change its mind. The Communist Party-owned Global Times reported last month that Fosun Pharma was still working with her. health authorities with its approval and the Shanghai authorities recently issued new policies that would allow the importation of the COVID-19 vaccine. Fosun, headquartered in Shanghai, did not answer questions about the announcement.
The Chinese National Board of Health has submitted questions to the National Board of Medicine, the National Board of Health and Welfare. This agency did not respond to fax requests for comment.
Meanwhile, China’s mRNA prevention center on Abogen Biosciences is expected to be set up in 2019 by Bo Ying, a US-trained scientist who once worked for Moderna.
The company has partnered with more established companies in the country such as Walvax, a private company established in 2001, by the College of Military Medical Sciences, a military medical research laboratory. Abogen has accumulated over $ 1.7 billion since 2020.
The company’s prevention candidate has successfully ousted another immune response in the first small test in a human being designed to evaluate safety, according to a apprenticeship published in the Lancet Microbe magazine.
The results were “impressive,” Drs. Vineeta Bal, who studies the immune system at the Indian Academy of Sciences and Research in Pune, India, although she said the similar direct immune response to the shot was caused by Pfizer and Moderna. Vaccines will help scientists evaluate its effectiveness.
But major investigations are needed to determine whether the shot works to prevent infection or signs are not over. Abogen did not respond to interview requests.
Even if the study can be completed and the treatment proved effective, producing the required millions of doses would be a challenge, experts say. Abogen built the factory in December 2020 with an estimated capacity of up to 120 million doses a year.
Providing prevention and quality assurance will be a difficult task because mRNA is still a relatively new technology, says Scott Wheelwright. chief executive officer at BioInno Bioscience, a Chinese think tank that interviewed Abogen.
Meanwhile, Chen, a Yale health expert, said the Chinese government should further protect its elderly people by trusting Pfizer. prevention and encourage trigger shots.
Using the Chinese word meaning “give back completely,” Chen said the change from “zero COVID” does not have to be complete or empty. “It doesn’t have to be a tang ping or glue with zero COVID,” Chen said. “I don’t think there are only two solutions, and we can stand on our own two feet.”
© 2022 Associated Press. All rights reserved. This material may not be reproduced, distributed, retransmitted or reposted without permission.
hint: Chinese Bomb on Local MRNA Prevention (2022, May 24) Retrieved May 24, 2022 from https://medicalxpress.com/news/2022-05-china- homegrown-mrna-vaccine.
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, any part may not be reproduced without our written permission. Content is provided for informational purposes only.
China’s bet on homegrown mRNA vaccines holds back nation Source link China’s bet on homegrown mRNA vaccines holds back nation